Stocks · News reference
Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The approval comes as Regentis prepares for the commercial launch of GelrinC® in Europe, enabling the Company to manufacture commercial product using a process that increases production yield by approximately 400%,
Read original at benzingaRegentis Biomaterials Ltd. (RGNT) stock rises after withdrawing its Form F-1 registration statement and accelerating European commercialization for GelrinC.
Read original at benzinga